A recent clinical trial conducted by Soroka University Medical Center and Israeli medical cannabis company Cannbit-Tikun Olam (TASE:TKUN) showed promising results, especially for treating post-traumatic stress disorder (PTSD), reported the Jerusalem Post.
Notably, a number of cannabis-medicated patients stopped or reduced their dosages of opioids by 52%, anti-psychotics by 36.9%, anti-epileptics by 35.7% and hypnotics and sedatives by 35.3%. Overall, over two-thirds of patients reported at least moderate improvement with no serious side effects, with 90.8% of treated PTSD patients being classified as therapeutic successes after six months.
